bench tops for 14 years and had a 30 pack year smoking history. Blood tests showed an IgE level of 297 IU/mL, increased antinuclear antibody (>2560-homogenous pattern) with a positive Scl-70 and Centromere Protein-B. He also had increased serum ACE levels (111 U/L). Full blood count, ESR, electrolytes, calcium and CK were normal and Rheumatoid Factor was negative. Spirometry revealed an FEV1/FVC of 1.95 L/2.1 L with predicted values of 58% and 49%. There was no change post bronchodilator. He had moderate lung restriction with a residual volume and total lung capacity of 35% and 55% predicted respectively. DLCO was 51% predicted, correcting to 88% predicted. Chest x-ray and CT scan of the chest showed multiple randomly distributed nodules within the lungs, some in perilymphatic distribution, associated with significant mediastinal and hilar adenopathy, with mass like areas of opacifications in the upper lobes, consistent with a conglomerate of coalesced nodules. Fine needle aspiration revealed benign reactive lymphadenopathy. Bronchoscopy washings revealed mainly macrophages with 8% eosinophils, and were negative for tuberculosis and bacterial growth. Trans-bronchial biopsy showed a fibrotic nodule of cellular silicosis. In light of his occupational history, this patient likely has silicosis with PMF. His examination findings and immunological results also point to scleroderma associated with silica exposure.
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Background and Aims: The aim of this study was to investigate the psychological health in IPF patients and their caregivers. Disease progression in IPF is variable, however, all patients eventually experience progressive decline in lung function, along with symptom burden. Very little is currently known about the patient's experience, the burden the disease places on family members and caregivers and the needs of both during the disease course.
Methods: A newly designed semi-structured clinical interview plus validated scales was used to investigate the prevalence of preparatory grief, anxiety and depression, in both IPF patients (diagnosed by ATS/ERS/JRS/ALAT criteria) and their caregivers. Within the IPF cohort, we used a validated Type D Personality scale in order to determine the relationship between personality and health-related quality of life outcomes.
Results: Our preliminary results indicate that preparatory grief is experienced by IPF patients and their caregivers around the time of diagnosis and can re-occur when there is an accelerated lung function decline. Patients report that at initial diagnosis, there was little to no psychological support offered, which exacerbated grief reactions.
Conclusion:
Our preliminary findings indicate that grief reactions are experienced by IPF patients and their caregivers and significantly contribute to the distress experienced. Based on these findings we will design and deliver a structured intervention for patient and caregiver support. Results: Of the 210 patients (163 CTD-ILD and 47 were IPF), The main HRCT features were subpleural distribution (97.1%), ground-glass opacities (58.1%), patchy attenuation (49.0%), reticular abnormality (46.7%), honeycombing(27.6%). 64.8% were female. The average age was 52.81 AE 13.86 years. The average HRCT score was 6.85 AE 3.85.
The 30-day effective therapy rate of all patients was 37.6%. By contrast, CTD-ILD occurs more commonly in females (P 0.004). IPF patients were more smokers (P 0.000). Cough (P 0.002) and sputum (P 0.000) were more frequent in IPF group. Reticular abnormality (P 0.019) and honeycombing (P 0.000) were more frequent in IPF group. Diffuse distribution at CT was more frequent in IPF group. In CTD-ILD group, the lymphocyte rate (P 0.006), albumin level (P 0.011) in blood and the HRCT score (P 0.000)were lower, the neutrophil-to-lymphocyte ratio in blood was higher (P 0.005). There was no difference in 30-day treatment response assessment between groups (P 0.566).
Conclusion: CTD-ILD occurs more commonly in females. IPF patients were more smokers, often had cough and sputum symptoms. Reticular abnormality and honeycombing were more frequent in IPF group. In CTD-ILD group, the lymphocyte rate, albumin level in blood and the HRCT score were lower, the neutrophil-to-lymphocyte ratio in blood was higher. There was no difference in 30-day treatment response assessment between groups. 
